Miguel Narvaez Encinas

Miguel Narvaez Encinas

Auto-generated profile, based on publicly available information

Miguel Narvaez Encinas

University of San Andres, 8390 Calacoto 21 street, La Paz, Bolivia, Bolivia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2026 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
MMMarcelo A. A. Moncada
Marcelo A. A. Moncada
MTMarco A. Narvaez Tamayo
Marco A. Narvaez Tamayo
MEMiguel A. Narvaez Encinas
Miguel A. Narvaez Encinas
MLMatteo Luigi Giuseppe Leoni
Matteo Luigi Giuseppe Leoni
Giustino VarrassiGiustino Varrassi
Giustino Varrassi
Chronic pain affects 20% of the global population, with current treatments achieving meaningful relief in less than 30% of patients. Growing evidence indicates that immuno-inflammatory mechanisms critically mediate the transition from acute to chronic pain, extending beyond sustained nociceptive input. This narrative review synthesizes current understanding of cellular and molecular immuno-inflammatory processes underlying pain chronification, emphasizing therapeutic implications of immune–neural interactions. Peripheral tissue injury triggers coordinated immune responses involving pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, tumor necrosis factor alpha (TNF-α), and algesic mediators that sensitize nociceptors. Infiltrating macrophages, T lymphocytes, and mast cells perpetuate pro-nociceptive environments. Centrally, microglial and astrocytic activation induces persistent neuroinflammation, synaptic remodeling, and enhanced excitatory neurotransmission while impairing descending inhibition. The balance between pro-inflammatory T helper 1 and T helper 17 (Th1/Th17) and anti-inflammatory T helper 2 and regulatory T cell (Th2/Treg) responses determines pain outcomes. Critically, premature suppression of acute inflammation with nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids may paradoxically promote chronification by disrupting endogenous resolution pathways mediated by specialized pro-resolving mediators and regulatory immune cells. Local inflammation proves more relevant than systemic inflammation for pain persistence. The gut–brain–immune axis emerges as a novel therapeutic target, with microbiota composition influencing pain susceptibility through immunomodulation. Finally, chronic pain represents a failure of natural resolution mechanisms rather than prolonged nociceptive activation. Understanding temporal dynamics of immune responses, individual variability, and sex-specific mechanisms opens avenues for precision medicine approaches. Future strategies should restore homeostatic mechanisms rather than simply suppress symptoms, incorporating biomarker-guided treatment selection and multimodal interventions targeting the complex immuno-inflammatory cascade.

30 July 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
Giustino VarrassiGiustino Varrassi
Giustino Varrassi
Y Van TranY Van Tran
Y Van Tran
Giacomo FarìGiacomo Farì
Giacomo Farì
MEMiguel Narvaez Encinas
Miguel Narvaez Encinas
Alberto CorrieroAlberto Corriero
Alberto Corriero
MLMatteo Luigi Giuseppe Leoni
Matteo Luigi Giuseppe Leoni
Neurodegenerative diseases represent a major and growing global health burden characterized by progressive neuronal dysfunction, axonal degeneration, and irreversible neural tissue loss. Increasing evidence identifies oxidative stress as one of several interacting pathogenic mechanisms in Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and several optic neuropathies. Interest has increasingly focused on the brain-retina axis, as the retina and optic nerve share structural, metabolic, and molecular features with the central nervous system and may provide accessible insights into neurodegeneration. This scoping review mapped current evidence on oxidative stress in neurodegeneration, emphasizing cranial nerve involvement, optic nerve vulnerability, retinal ganglion cell degeneration, visual dysfunction, oxidative biomarkers, and emerging therapeutic strategies. The review followed established methodological frameworks and PRISMA-ScR recommendations; no formal risk-of-bias appraisal was undertaken, consistent with scoping-review methodology. The literature shows that oxidative stress interacts with mitochondrial dysfunction, neuroinflammation, impaired mitophagy, ferroptosis, and altered bioenergetics, contributing to neuronal injury in cerebral and retinal disorders. Retinal ganglion cells appear particularly vulnerable because of their high metabolic demands and reliance on oxidative phosphorylation. Glaucoma and other optic neuropathies share molecular signatures with central neurodegenerative diseases. Retinal imaging and oxidative biomarkers show promise for diagnosis, monitoring, and stratification. The evidence base is nonetheless dominated by preclinical work; biomarker performance is inconsistent across matrices and assay platforms and most antioxidant clinical trials have been negative. Oxidative stress is therefore best regarded as one interacting node of a broader pathogenic network rather than a universal or predominant driver and the brain-retina continuum as a mechanistically plausible but not yet clinically validated framework for biomarker-guided neuroprotection.

3 August 2026 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
Y Van TranY Van Tran
Y Van Tran
Phong Van PhamPhong Van Pham
Phong Van Pham
MEMiguel Narvaez Encinas
Miguel Narvaez Encinas
Piercarlo Sarzi-PuttiniPiercarlo Sarzi-Puttini
Piercarlo Sarzi-Puttini
DMDariusz Myrcik
Dariusz Myrcik
Giustino VarrassiGiustino Varrassi
Giustino Varrassi
Regenerative medicine has emerged as a transformative paradigm in contemporary healthcare, shifting the therapeutic focus from symptomatic management toward the restoration of tissue structure and function through biologically active interventions. Within this framework, adipose-derived products have attracted substantial interest owing to their relative abundance, ease of harvesting, and rich cellular and paracrine composition, including mesenchymal stromal cells, pericytes, and bioactive mediators with immunomodulatory potential. Among these technologies, microfragmented adipose tissue (MFAT) constitutes an innovative, minimally manipulated approach because it preserves the native stromal vascular niche and extracellular matrix architecture while avoiding enzymatic processing. This characteristic not only maintains biological integrity but also facilitates regulatory compliance in multiple jurisdictions. This narrative review provides a comprehensive synthesis of the current evidence on microfragmented adipose tissue in pain management, integrating biological rationale, mechanistic insights, and clinical applications across musculoskeletal disorders and chronic pain conditions. Particular attention is devoted to its capacity to modulate inflammatory pathways, promote angiogenesis, and support tissue regeneration within complex pathological environments. In addition, the review critically appraises the methodological limitations of existing clinical studies, including heterogeneity of design and limited high-quality randomized evidence. Finally, future perspectives are explored, emphasizing the integration of precision medicine approaches, biomarker-driven patient stratification, and combinatorial regenerative strategies to optimize therapeutic outcomes.

13 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Y Van TranY Van Tran
Y Van Tran
Phong Van PhamPhong Van Pham
Phong Van Pham
MEMiguel Narvaez Encinas
Miguel Narvaez Encinas
Piercarlo Sarzi-PuttiniPiercarlo Sarzi-Puttini
Piercarlo Sarzi-Puttini
DMDariusz Myrcik
Dariusz Myrcik
Giustino VarrassiGiustino Varrassi
Giustino Varrassi
Regenerative medicine has emerged as a transformative paradigm in contemporary healthcare, shifting the therapeutic focus from symptomatic management toward the restoration of tissue structure and function through biologically active interventions. Within this framework, adipose-derived products have attracted substantial interest owing to their relative abundance, ease of harvesting, and rich cellular and paracrine composition, including mesenchymal stromal cells, pericytes, and bioactive mediators with immunomodulatory potential. Among these technologies, Lipogems® represents an innovative approach based on minimally manipulated microfragmented adipose tissue, because it preserves the native stromal vascular niche and extracellular matrix architecture while avoiding enzymatic processing. This characteristic not only maintains biological integrity but also facilitates regulatory compliance in multiple jurisdictions. This narrative review provides a comprehensive synthesis of the current evidence on Lipogems®, integrating biological rationale, mechanistic insights, and clinical applications across musculoskeletal disorders and chronic pain conditions. Particular attention is devoted to its capacity to modulate inflammatory pathways, promote angiogenesis, and support tissue regeneration within complex pathological environments. In addition, the review critically appraises the methodological limitations of existing clinical studies, including heterogeneity of design and limited high-quality randomized evidence. Finally, future perspectives are explored, emphasizing the integration of precision medicine approaches, biomarker-driven patient stratification, and combinatorial regenerative strategies aimed at optimizing therapeutic outcomes.

1 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Giustino VarrassiGiustino Varrassi
Giustino Varrassi
Y Van TranY Van Tran
Y Van Tran
Giacomo FarìGiacomo Farì
Giacomo Farì
MEMiguel Narvaez Encinas
Miguel Narvaez Encinas
Phong Van PhamPhong Van Pham
Phong Van Pham
MLMatteo Luigi Giuseppe Leoni
Matteo Luigi Giuseppe Leoni
Neurodegenerative diseases represent a major and growing global health burden characterized by progressive neuronal dysfunction, axonal degeneration, and irreversible neural tissue loss. Increasing evidence identifies oxidative stress as a central pathogenic mechanism in Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and several optic neuropathies. Interest has increasingly focused on the brain-retina axis, as the retina and optic nerve share structural, metabolic, and molecular features with the central nervous system and may provide accessible insights into neurodegeneration.This scoping review mapped current evidence on oxidative stress in neurodegeneration, emphasizing cranial nerve involvement, optic nerve vulnerability, retinal ganglion cell degeneration, visual dysfunction, oxidative biomarkers, and emerging therapeutic strategies. The review followed established methodological frameworks and PRISMA-ScR recommendations.The literature shows that oxidative stress interacts with mitochondrial dysfunction, neuroinflammation, impaired mitophagy, ferroptosis, and altered bioenergetics, contributing to neuronal injury in cerebral and retinal disorders. Retinal ganglion cells appear particularly vulnerable because of their high metabolic demands and reliance on oxidative phosphorylation. Glaucoma and other optic neuropathies share molecular signatures with central neurodegenerative diseases. Retinal imaging and oxidative biomarkers show promise for diagnosis, monitoring, and stratification. Overall, oxidative stress emerges as a convergent mechanism across the brain-retina continuum, supporting biomarker-driven neuroprotection and precision medicine.

30 April 2026 in Revista Dermatológica Centro Uraga
Verified
Journal Article
Open access
PDF file
MGMelany Liza Ayala Gonzales
Melany Liza Ayala Gonzales
GAGabriela Ayala
Gabriela Ayala
MNMiguel Narvaez
Miguel Narvaez
Se ha postulado una disfunción de la microbiota intestinal en las alteraciones de la piel como la psoriasis, dermatitis atópica, acné, vitíligo, rosácea, enfermedades autoinmunes, entre otras. Durante este estudio, se realizó una revisión de artículos publicados entre enero de 2019 y octubre de 2024 que identificaron y analizaron las dermatopatías en pacientes con disbiosis, siendo las más analizadas la dermatitis atópica y la psoriasis. Los estudios en psoriasis donde se asociaron al tratamiento probióticos o prebióticos mostraron una mejora en el Índice de Severidad de la Psoriasis (PASI) y en el Índice de Calidad de Vida de Dermatología (DLQI), así como una disminución de IL-6; también se asocia a menor tasa de brotes (20% vs. placebo del 41.9%). Respecto a la dermatitis atópica, también se evidenció una disminución del Scoring Atopic Dermatitis (SCORAD) tras la instauración de prebióticos. Los trasplantes fecales en las distintas patologías mostraron cambios significativos en la microbiota intestinal, lo que podría influir en la mejora clínica. Ninguno de los estudios reportó efectos adversos graves relacionados con las intervenciones.